Mikhail Blagosklonny

Mikhail Blagosklonny was a Russian-American oncologist and biogerontologist known for his pioneering research on the mTOR pathway and the anti-aging potential of the drug rapamycin. He served as a professor of oncology at the Roswell Park Comprehensive Cancer Center in Buffalo, New York, and was the editor-in-chief of the journals Cell Cycle and Aging. Blagosklonny was a prominent and often controversial advocate for rapamycin as a therapeutic agent to slow aging and treat age-related diseases, proposing the hyperfunction theory of aging as an alternative to traditional wear-and-tear models.

Early life and education

Mikhail Blagosklonny was born in Leningrad within the Soviet Union. He pursued his medical education at the prestigious First Pavlov State Medical University of St. Peterburg, one of the oldest and most renowned medical schools in Russia. Following his graduation, he completed his PhD in experimental medicine and cardiology, laying an early foundation in biomedical research. His early career in the Soviet Union provided a rigorous training ground before he eventually emigrated to the United States to further his scientific work.

Academic career and research

After moving to the United States, Blagosklonny held research positions at several prominent institutions, including the Ordway Research Institute in Albany, New York. His primary academic appointment was as a professor of oncology at the Roswell Park Comprehensive Cancer Center, a National Cancer Institute-designated comprehensive cancer center. A prolific writer, he authored hundreds of scientific papers and served as the editor-in-chief of the peer-reviewed journals Cell Cycle and Aging. His research broadly focused on cellular senescence, apoptosis, and the molecular mechanisms of cancer, with a particular emphasis on the PI3K/AKT/mTOR pathway as a central regulator of both cell growth and aging.

Rapamycin and aging research

Blagosklonny is most widely recognized for his vigorous advocacy of rapamycin (also known as sirolimus) as a potential geroprotector. He argued that by inhibiting the mTOR pathway, rapamycin could decelerate the aging process and prevent multiple age-related diseases, including cancer, Alzheimer's disease, and cardiovascular disease. This work was closely associated with the research of other notable scientists in the field, such as David A. Sinclair and Nir Barzilai. Blagosklonny formulated the hyperfunction theory of aging, which posits that aging is driven by the continued, inappropriate activity of growth-promoting pathways like mTOR post-development, rather than by mere accumulation of damage.

Controversies and criticism

Blagosklonny's work, particularly his strong personal advocacy for the prophylactic use of rapamycin in healthy individuals, attracted significant controversy and criticism from within the scientific community. Critics, including researchers from the National Institute on Aging, argued that the long-term safety profile of rapamycin in non-patient populations was not sufficiently established, citing potential side effects like immunosuppression and metabolic disturbances. Some academics accused him of premature translation and sensationalism, while others questioned aspects of the hyperfunction theory of aging. These debates were frequently aired in the pages of journals like Nature and Science.

Personal life and death

Mikhail Blagosklonny was known to be a private individual regarding his personal affairs. He was married and had children. Following a period of illness, he died on October 19, 2024, in Rochester, New York. His death was announced by his colleagues at Roswell Park Comprehensive Cancer Center and the journal Aging, prompting numerous tributes from researchers in the fields of biogerontology and oncology who recognized his impactful, if contentious, contributions to the science of aging.

Category:1959 births Category:2024 deaths Category:American oncologists Category:American gerontologists Category:Russian emigrants to the United States